carboplatin + etoposide + topotecan

This is a combination chemotherapy regimen consisting of three small molecule drugs—carboplatin, etoposide, and topotecan—used primarily in the treatment of small cell lung cancer (SCLC). - **Carboplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA synthesis and function. - **Etoposide** is a topoisomerase II inhibitor that causes DNA strand breaks by preventing the re-ligation of double-stranded breaks induced by the enzyme. - **Topotecan** is a topoisomerase I inhibitor that prevents DNA repair by stabilizing the cleavable complex between DNA and topoisomerase I, leading to apoptosis in rapidly dividing cells. The combination has been studied as first-line therapy for SCLC and has shown tolerability with manageable toxicity profiles but without significant improvement in overall response rate or survival compared to other platinum-etoposide regimens[1][5]. The regimen may be used sequentially or concurrently depending on protocol design.

Other names

carboplatin plus etoposide plus topotecanT/C/E combination